End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36 NZD | +0.93% | +4.96% | +1.41% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.58 times its sales, is clearly overvalued in comparison with peers.
- Sales forecast by analysts have been recently revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- With a 2024 P/E ratio at 22.46 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.41% | 4.19B | B- | ||
-1.88% | 24.09B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.97B | B- | ||
-3.28% | 7.84B | C | ||
+2.26% | 4.66B | B- | ||
+17.12% | 4.32B | B+ | ||
-3.02% | 3.89B | B | ||
+21.42% | 3.62B | C+ | ||
+8.64% | 3.41B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EBO Stock
- Ratings EBOS Group Limited